News

€6 million in new capital and new CEO for Cristal Therapeutics

Date: 15/12/2014

15 December 2014, Maastricht, The Netherlands  – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding and Beheer Innovatiefonds Provincie Limburg also contributed. The financing will be used to launch the first clinical study of Cristal Therapeutics’ most advanced therapy, CriPec® docetaxel.

Co-founder Dr Joost Holthuis has succeeded its founder Dr Cristianne Rijcken as CEO of the company, effective since December 1, 2014. Dr Holthuis has an extensive career in the biotech field and founded OctoPlus, which was listed on the Amsterdam stock exchange, and CEO of between 1995 and 2008. In addition to serving on supervisory boards of various highly promising biotech start-ups, Dr Holthuis is also a venture partner at biotech venture capital investor BioGeneration in Naarden.

Dr Rijcken, CEO since its incorporation in 2011, will become Chief Scientific Officer (CSO). Dr Rijcken, together with Joost Holthuis, launched Cristal Therapeutics as a spin-off of the Department of Pharmaceutics of Utrecht University.

Find the full press release here.